慢性静脉疾病临床实践指南质量的系统评价
该系统评价采用AGREE II工具评估慢性静脉疾病(CVD)临床实践指南(CPGs)的方法学质量,检索Medline和Embase数据库后纳入6部2004至2018年发表的欧美指南。结果显示评价者间信度高(ICC>0.8,P≤.002),仅1部指南平均得分95.83%属高质量,其余5部得分29%至71%,各指南在利益相关者参与和适用性方面普遍表现不佳。
要点
- AGREE II工具评价CVD指南的评分可重复性好,ICC>0.8。
- 仅1部CVD指南方法学质量高,平均得分95.83%。
- 多数指南在利益相关者参与和临床适用性方面薄弱。
核心结论
- AGREE II工具在不同评价者间评分可重复。
- 仅识别出1部方法学高质量的CVD临床实践指南。
- AGREE II可用于识别指南中需改进方法学质量的方面。
研究设计与样本
- 系统评价,通过Medline和Embase数据库检索CVD相关指南。
- 纳入标准为过去20年以英文发表的循证CPGs,排除共识文件、专家意见及仅提供诊断或治疗指导的研究。
- 共纳入6部2004至2018年发表的欧美指南,由4名独立评价者使用AGREE II工具在6个领域进行评估。
主要发现
- 6部指南所有评价者间信度高,ICC>0.8(P≤.002)。
- 1部指南所有领域平均得分95.83%,属高质量。
- 其余5部指南得分范围为29%至71%。
- 指南在利益相关者参与和适用性评估方面普遍表现不佳。
临床怎么用
- 临床选用CVD指南时应优先参考AGREE II评分高的指南。
- 指南制定者可利用AGREE II识别并改进方法学薄弱环节。
局限性
- 仅纳入英文发表的指南,可能遗漏非英语指南。
- 仅纳入2004至2018年间的指南,未涵盖更近期指南。
- 纳入指南均来自欧洲和北美,代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our aim was to assess the methodologic quality of clinical practice guidelines (CPGs), which inform the diagnosis and management of chronic venous disease (CVD), using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool. METHODS: A systematic review was performed through the Medline and Embase databases to identify CPGs relevant to CVD. The included articles were evidence-based CPGs available in English and reported in the past 20 years. Consensus documents, expert opinions, and studies providing guidance for diagnosis or treatment alone were excluded. Four independent reviewers assessed the CPGs using the AGREE II tool across six domains. Overall quality scaled scores were calculated for each guideline, and the interrater reliability was measured using an intraclass correlation coefficient. SPSS, version 25 (IBM Corp, Armonk, NY) was used for statistical analysis. RESULTS: Six CPGs reported from 2004 to 2018 were identified; all were of European and North American origin. The interrater reliability when scoring each CPG was high, with an intraclass correlation coefficient of >0.8 (P ≤ .002) for all six CPGs. One CPG had an average score of 95.83% across all domains, qualifying as a high quality CPG. The remaining five CPGs had scores ranging from 29% to 71%. The CPGs generally performed poorly in outlining stakeholder involvement and evaluating the applicability of the guideline to clinical practice. CONCLUSIONS: Scores from the AGREE II tool were reproducible when different users evaluated the CPGs. We identified one CPG for CVD of high methodologic quality. The AGREE II appraisal tool can be used to identify aspects of CPGs that can be developed to improve their methodologic quality.
引用
- Salim S, Tan M, Geoghegan L, et al. A systematic review assessing the quality of clinical practice guidelines in chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33249107. doi:10.1016/j.jvsv.2020.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。